Nestlé/Galderma Expands U.S. Dermal-Filler Stake As Valeant Raises Bid For Allergan
This article was originally published in The Gray Sheet
Executive Summary
Swiss dermatology firm Galderma, soon to be a Nestlé subsidiary, will gain access to the Sculptra dermal filler device and a North American sales presence for four other medical aesthetics products in a $1.4 billion sell-off by Valeant intended to strengthen its position to buy Allergan.
You may also be interested in...
Valeant/Pershing To Allergan: Last Chance To Negotiate
After surprising investors by increasing its bid for Allergan for a second time in one week, Valeant and its activist investor partner Pershing Square, urged management to negotiate before a special meeting is convened to oust the company’s board of directors.
Valeant To Allergan: Anything You Can Do I Can Do Better
The Canadian specialty pharma says its streamlined business model could sufficiently pull costs out of Allergan’s business dealings, including line extensions and post-marketing commitments.
Allergan Attacks Valeant’s History With Mergers Ahead Of Potential New Offer
The Botox-maker wanted to make its case before Valeant could up its offer, which is expected later this week, arguing that Valeant paints a rosier picture than is realistic.